Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients
Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD...
Gespeichert in:
Veröffentlicht in: | American journal of kidney diseases 2009-12, Vol.54 (6), p.1072-1080 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1080 |
---|---|
container_issue | 6 |
container_start_page | 1072 |
container_title | American journal of kidney diseases |
container_volume | 54 |
creator | Raj, Dominic S.C., MD Carrero, Juan J., PhD Shah, Vallabh O., PhD Qureshi, Abdul R., MD Bárány, Peter, MD Heimbürger, Olof, MD Lindholm, Bengt, MD Ferguson, Jennet, BA Moseley, Pope L., MD Stenvinkel, Peter, MD |
description | Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting & Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers. |
doi_str_mv | 10.1053/j.ajkd.2009.06.022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_556042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0272638609009408</els_id><sourcerecordid>733603362</sourcerecordid><originalsourceid>FETCH-LOGICAL-c577t-7137bc3dcf9c3699e4470fb5277d29512a247c1d04a32998677784a3199de29a3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhiMEokvhD3BAuSAuTfBHYscSqlQtH620iEoFcbS89qQ468TFThbtv8fRRoVy4GDZmnnmnZHfybKXGJUY1fRtV6puZ0qCkCgRKxEhj7IVrgktWEObx9kKEU4KRht2kj2LsUMJpIw9zU6w4JSKqlll32-8m7YO8vV7XOUb2IOLZ_nVMEJwMO3skLOzXA0m_-zDqJwdD_lF74fb_DrAXjkYxvwSem-scodoY36tRpuC8Xn2pFUuwovlPs2-ffzwdX1ZbL58ulpfbApdcz4WHFO-1dToVmjKhICq4qjd1oRzQ0SNiSIV19igSlEiRMM45016YyEMEKHoaVYcdeMvuJu28i7YXoWD9MrKJbRLL5B1zVBFEn9-5FOmB6PTrEG5B2UPM4P9IW_9XhLecFE3SeDNIhD8zwniKHsbNTinBvBTlOljGUpnbkWOpA4-xgDtfReM5Gyg7ORsoJwNlIjJZGAqevX3fH9KFscS8HoBVNTKtUEN2sZ7jhDcCCbqxL07cslQ2FsIMurkjAZjA-hRGm__P8f5P-Xa2cGmjjs4QOz8FIbkq8QyEonkzbxq86YhkUQq1NDfRFbOKg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733603362</pqid></control><display><type>article</type><title>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>SWEPUB Freely available online</source><creator>Raj, Dominic S.C., MD ; Carrero, Juan J., PhD ; Shah, Vallabh O., PhD ; Qureshi, Abdul R., MD ; Bárány, Peter, MD ; Heimbürger, Olof, MD ; Lindholm, Bengt, MD ; Ferguson, Jennet, BA ; Moseley, Pope L., MD ; Stenvinkel, Peter, MD</creator><creatorcontrib>Raj, Dominic S.C., MD ; Carrero, Juan J., PhD ; Shah, Vallabh O., PhD ; Qureshi, Abdul R., MD ; Bárány, Peter, MD ; Heimbürger, Olof, MD ; Lindholm, Bengt, MD ; Ferguson, Jennet, BA ; Moseley, Pope L., MD ; Stenvinkel, Peter, MD</creatorcontrib><description>Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting & Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.</description><identifier>ISSN: 0272-6386</identifier><identifier>EISSN: 1523-6838</identifier><identifier>DOI: 10.1053/j.ajkd.2009.06.022</identifier><identifier>PMID: 19733948</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Biomarkers - blood ; C-reactive protein (CRP) ; C-Reactive Protein - metabolism ; Emergency and intensive care: renal failure. Dialysis management ; Endotoxin ; Endotoxins - blood ; Female ; Follow-Up Studies ; hemodialysis ; Humans ; Inflammation - blood ; Intensive care medicine ; interleukin 6 (IL-6) ; Interleukin-6 - blood ; Lipopolysaccharide Receptors - blood ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Nephrology ; Nephrology. Urinary tract diseases ; pentraxin 3 ; Predictive Value of Tests ; Prospective Studies ; Protein-Energy Malnutrition - blood ; protein-energy wasting ; Renal Dialysis ; Renal Insufficiency - blood ; Renal Insufficiency - mortality ; Renal Insufficiency - therapy ; Serum Amyloid P-Component - metabolism ; Survival Rate ; Sweden</subject><ispartof>American journal of kidney diseases, 2009-12, Vol.54 (6), p.1072-1080</ispartof><rights>National Kidney Foundation, Inc.</rights><rights>2009 National Kidney Foundation, Inc.</rights><rights>2015 INIST-CNRS</rights><rights>2009 The National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c577t-7137bc3dcf9c3699e4470fb5277d29512a247c1d04a32998677784a3199de29a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0272638609009408$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,550,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22189695$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19733948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:119661937$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Raj, Dominic S.C., MD</creatorcontrib><creatorcontrib>Carrero, Juan J., PhD</creatorcontrib><creatorcontrib>Shah, Vallabh O., PhD</creatorcontrib><creatorcontrib>Qureshi, Abdul R., MD</creatorcontrib><creatorcontrib>Bárány, Peter, MD</creatorcontrib><creatorcontrib>Heimbürger, Olof, MD</creatorcontrib><creatorcontrib>Lindholm, Bengt, MD</creatorcontrib><creatorcontrib>Ferguson, Jennet, BA</creatorcontrib><creatorcontrib>Moseley, Pope L., MD</creatorcontrib><creatorcontrib>Stenvinkel, Peter, MD</creatorcontrib><title>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting & Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.</description><subject>Aged</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>C-reactive protein (CRP)</subject><subject>C-Reactive Protein - metabolism</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Endotoxin</subject><subject>Endotoxins - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>hemodialysis</subject><subject>Humans</subject><subject>Inflammation - blood</subject><subject>Intensive care medicine</subject><subject>interleukin 6 (IL-6)</subject><subject>Interleukin-6 - blood</subject><subject>Lipopolysaccharide Receptors - blood</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology</subject><subject>Nephrology. Urinary tract diseases</subject><subject>pentraxin 3</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Protein-Energy Malnutrition - blood</subject><subject>protein-energy wasting</subject><subject>Renal Dialysis</subject><subject>Renal Insufficiency - blood</subject><subject>Renal Insufficiency - mortality</subject><subject>Renal Insufficiency - therapy</subject><subject>Serum Amyloid P-Component - metabolism</subject><subject>Survival Rate</subject><subject>Sweden</subject><issn>0272-6386</issn><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp9kk1v1DAQhiMEokvhD3BAuSAuTfBHYscSqlQtH620iEoFcbS89qQ468TFThbtv8fRRoVy4GDZmnnmnZHfybKXGJUY1fRtV6puZ0qCkCgRKxEhj7IVrgktWEObx9kKEU4KRht2kj2LsUMJpIw9zU6w4JSKqlll32-8m7YO8vV7XOUb2IOLZ_nVMEJwMO3skLOzXA0m_-zDqJwdD_lF74fb_DrAXjkYxvwSem-scodoY36tRpuC8Xn2pFUuwovlPs2-ffzwdX1ZbL58ulpfbApdcz4WHFO-1dToVmjKhICq4qjd1oRzQ0SNiSIV19igSlEiRMM45016YyEMEKHoaVYcdeMvuJu28i7YXoWD9MrKJbRLL5B1zVBFEn9-5FOmB6PTrEG5B2UPM4P9IW_9XhLecFE3SeDNIhD8zwniKHsbNTinBvBTlOljGUpnbkWOpA4-xgDtfReM5Gyg7ORsoJwNlIjJZGAqevX3fH9KFscS8HoBVNTKtUEN2sZ7jhDcCCbqxL07cslQ2FsIMurkjAZjA-hRGm__P8f5P-Xa2cGmjjs4QOz8FIbkq8QyEonkzbxq86YhkUQq1NDfRFbOKg</recordid><startdate>20091201</startdate><enddate>20091201</enddate><creator>Raj, Dominic S.C., MD</creator><creator>Carrero, Juan J., PhD</creator><creator>Shah, Vallabh O., PhD</creator><creator>Qureshi, Abdul R., MD</creator><creator>Bárány, Peter, MD</creator><creator>Heimbürger, Olof, MD</creator><creator>Lindholm, Bengt, MD</creator><creator>Ferguson, Jennet, BA</creator><creator>Moseley, Pope L., MD</creator><creator>Stenvinkel, Peter, MD</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20091201</creationdate><title>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</title><author>Raj, Dominic S.C., MD ; Carrero, Juan J., PhD ; Shah, Vallabh O., PhD ; Qureshi, Abdul R., MD ; Bárány, Peter, MD ; Heimbürger, Olof, MD ; Lindholm, Bengt, MD ; Ferguson, Jennet, BA ; Moseley, Pope L., MD ; Stenvinkel, Peter, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c577t-7137bc3dcf9c3699e4470fb5277d29512a247c1d04a32998677784a3199de29a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>C-reactive protein (CRP)</topic><topic>C-Reactive Protein - metabolism</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Endotoxin</topic><topic>Endotoxins - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>hemodialysis</topic><topic>Humans</topic><topic>Inflammation - blood</topic><topic>Intensive care medicine</topic><topic>interleukin 6 (IL-6)</topic><topic>Interleukin-6 - blood</topic><topic>Lipopolysaccharide Receptors - blood</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology</topic><topic>Nephrology. Urinary tract diseases</topic><topic>pentraxin 3</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Protein-Energy Malnutrition - blood</topic><topic>protein-energy wasting</topic><topic>Renal Dialysis</topic><topic>Renal Insufficiency - blood</topic><topic>Renal Insufficiency - mortality</topic><topic>Renal Insufficiency - therapy</topic><topic>Serum Amyloid P-Component - metabolism</topic><topic>Survival Rate</topic><topic>Sweden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raj, Dominic S.C., MD</creatorcontrib><creatorcontrib>Carrero, Juan J., PhD</creatorcontrib><creatorcontrib>Shah, Vallabh O., PhD</creatorcontrib><creatorcontrib>Qureshi, Abdul R., MD</creatorcontrib><creatorcontrib>Bárány, Peter, MD</creatorcontrib><creatorcontrib>Heimbürger, Olof, MD</creatorcontrib><creatorcontrib>Lindholm, Bengt, MD</creatorcontrib><creatorcontrib>Ferguson, Jennet, BA</creatorcontrib><creatorcontrib>Moseley, Pope L., MD</creatorcontrib><creatorcontrib>Stenvinkel, Peter, MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raj, Dominic S.C., MD</au><au>Carrero, Juan J., PhD</au><au>Shah, Vallabh O., PhD</au><au>Qureshi, Abdul R., MD</au><au>Bárány, Peter, MD</au><au>Heimbürger, Olof, MD</au><au>Lindholm, Bengt, MD</au><au>Ferguson, Jennet, BA</au><au>Moseley, Pope L., MD</au><au>Stenvinkel, Peter, MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2009-12-01</date><risdate>2009</risdate><volume>54</volume><issue>6</issue><spage>1072</spage><epage>1080</epage><pages>1072-1080</pages><issn>0272-6386</issn><eissn>1523-6838</eissn><abstract>Background CD14 is a pattern-recognition receptor that has a central immunomodulatory role in proinflammatory signaling in response to a variety of ligands, including endotoxin. CD14 protein is present in 2 forms: soluble (sCD14) and membrane bound. Here, we studied the implications of increased sCD14 levels in hemodialysis patients. We hypothesized that sCD14 level increase may link to cytokine activation and protein-energy wasting, predisposing to increased mortality risk. Study Design Prospective observational study of prevalent hemodialysis patients. Setting & Participants 211 prevalent hemodialysis patients, median age of 65 years, with 29 months of vintage dialysis time followed up for mortality for a median of 31 months. Predictors Tertiles of baseline circulating sCD14 levels corresponding to less than 2.84, 2.85 to 3.62, and greater than 3.63 μg/mL. Outcome The major outcome of interest was all-cause mortality. Measurements sCD14 and endotoxin, together with other markers of inflammation and protein-energy wasting. Results Median sCD14 level was 3.2 μg/mL (25th to 75th percentile, 2.7 to 3.9). sCD14 level correlated positively with C-reactive protein, interleukin 6, endotoxin, and pentraxin 3 levels and negatively with serum albumin level, muscle mass, and handgrip strength. Patients with increased sCD14 levels had lower body mass index and increased prevalence of muscle atrophy. Patients within the highest sCD14 tertile had a crude morality hazard ratio of 1.94 (95% confidence interval, 1.13 to 3.32) that persisted after adjustment for multiple confounders (hazard ratio, 3.11; 95% confidence interval, 1.49 to 6.46). In patients with persistent inflammation, the presence of a concurrent sCD14 level increase gradually increased mortality risk, but this effect was less than multiplicative and failed to show a statistical interaction. Limitations Those inherent to an observational study. Conclusions sCD14 level is associated with inflammation and protein-energy wasting in hemodialysis patients. It is a strong and independent predictor of mortality that warrants further assessment in the clinical setting regarding its usefulness as a complementary prognosticator to other general inflammatory markers.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>19733948</pmid><doi>10.1053/j.ajkd.2009.06.022</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0272-6386 |
ispartof | American journal of kidney diseases, 2009-12, Vol.54 (6), p.1072-1080 |
issn | 0272-6386 1523-6838 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_556042 |
source | MEDLINE; Elsevier ScienceDirect Journals; SWEPUB Freely available online |
subjects | Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Biomarkers - blood C-reactive protein (CRP) C-Reactive Protein - metabolism Emergency and intensive care: renal failure. Dialysis management Endotoxin Endotoxins - blood Female Follow-Up Studies hemodialysis Humans Inflammation - blood Intensive care medicine interleukin 6 (IL-6) Interleukin-6 - blood Lipopolysaccharide Receptors - blood Longitudinal Studies Male Medical sciences Middle Aged Nephrology Nephrology. Urinary tract diseases pentraxin 3 Predictive Value of Tests Prospective Studies Protein-Energy Malnutrition - blood protein-energy wasting Renal Dialysis Renal Insufficiency - blood Renal Insufficiency - mortality Renal Insufficiency - therapy Serum Amyloid P-Component - metabolism Survival Rate Sweden |
title | Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis Patients |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T02%3A19%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20CD14%20Levels,%20Interleukin%206,%20and%20Mortality%20Among%20Prevalent%20Hemodialysis%20Patients&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Raj,%20Dominic%20S.C.,%20MD&rft.date=2009-12-01&rft.volume=54&rft.issue=6&rft.spage=1072&rft.epage=1080&rft.pages=1072-1080&rft.issn=0272-6386&rft.eissn=1523-6838&rft_id=info:doi/10.1053/j.ajkd.2009.06.022&rft_dat=%3Cproquest_swepu%3E733603362%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733603362&rft_id=info:pmid/19733948&rft_els_id=S0272638609009408&rfr_iscdi=true |